CEUS radiomics significantly improved the performance of CUS radiomics in predicting Luminal A, HER2-overexpression, HR-positivity, and HER2-positivity breast cancers subtype (p=0.000013, 0.003, 0.004, and 0.000145). This evidence concerns the gene ERBB2 and breast carcinoma.